logo

For the Inventor, By the Inventor

Ardmore, PA, United States of America

Robert M DeMarinis

USPTO Granted Patents = 35

Average Co-Inventor Count = 1.5

ph-index = 8

Forward Citations = 237(Granted Patents)


Location History:

  • King of Prussia, PA (US) (1976 - 1979)
  • Ardmore, PA (US) (1980 - 1997)

Company Filing History:

goldMedal20 out of 344 
 
Smithkline Corporation
 patents
silverMedal9 out of 207 
 
Smithkline Beckman Corporation
 patents
bronzeMedal6 out of 2,198 
 
Smithkline Beecham Corporation
 patents

Years Active: 1976-1997

Loading Chart...
35 patents (USPTO):Explore Patents
1. 5639748 - 6,9-disubstituted benzazepines having .alpha.-adrenoceptor blocking (1997-06-17),
2. 5599810 - Furo- and thieno[4,3,2-ef][3]benzazepines useful as alpha adrenergic (1997-02-04),
3. 5006521 - .alpha.-adrenergic receptor antagonists and methods of use thereas (1991-04-09),
4. 4978660 - .alpha.-adrenergic receptor antagonists (1990-12-18),
5. 4963547 - Alpha-andrenergic receptor antagonists and use thereas (1990-10-16),
6. 4959360 - .alpha.-adrenergic receptor antagonists (1990-09-25),
7. 4849362 - Fluorescent intracellular calcium indicators (1989-07-18),
8. 4686218 - Use of 6-chloro-3-methyl-1H-2,3,4,5-tetrahydro-3-benzazepine-n-oxide, as (1987-08-11),
9. 4683229 - 6-halo-9-alkenyleneoxy-3-alkyl-2,3,4,5-tetrahydro-(1H-3)-benzazepines (1987-07-28),
10. 4652642 - Azidobenzazepines (1987-03-24),
11. 4507320 - Dopaminergic agonist (1985-03-26),
12. 4496558 - Pharmaceutical compositions and methods for producing alpha antagonism (1985-01-29),
13. 4469634 - Allyloxy- and allylthio-2,3,4,5-tetrahydro-1H-3-benzazepines (1984-09-04),
14. 4465677 - Pharmaceutical compositions and method of producing alpha.sub.2 (1984-08-14),
15. 4444782 - 2(4-tert.-Butyl-2,6-dichlorophenyl-imino)imidazolidine and use as an (1984-04-24),

Title: Celebrating the Innovative Journey of Robert M. DeMarinis

Introduction: Robert M. DeMarinis, a renowned inventor based in Ardmore, Pennsylvania, has made significant contributions to the field of pharmaceuticals through his innovative work. With an impressive portfolio of 35 patents, DeMarinis has displayed a strong commitment to advancing medical science.

Latest Patents: Among his latest innovations are several important patents, including "6,9-disubstituted benzazepines having α-adrenoceptor blocking properties" and "Furo- and thieno[4,3,2-ef][3]benzazepines useful as alpha adrenergic antagonists." These patents detail compounds that serve as effective alpha-adrenergic receptor antagonists and present various pharmaceutical compositions and treatment methods designed to enhance patient care.

Career Highlights: Throughout his career, Robert M. DeMarinis has held pivotal roles at notable companies, including SmithKline Corporation and SmithKline Beecham Corporation. His work at these organizations has allowed him to develop groundbreaking pharmaceutical inventions that address critical health issues.

Collaborations: DeMarinis has collaborated with several esteemed colleagues in the field, including Dinubhai H. Shah and John J. Lafferty. These partnerships have fostered an environment of innovation and excellence, leading to significant advancements in pharmaceutical research and development.

Conclusion: The contributions of Robert M. DeMarinis highlight the vital role inventors play in the advancement of medicine. His patents not only demonstrate his expertise but also his dedication to improving health outcomes through innovative solutions. As he continues his work, the impact of his inventions will undoubtedly resonate within the pharmaceutical industry for years to come.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…